Does Concizumab Interact with Fviii?
CDI records a major classification for Concizumab and Fviii. The stored summary is: High and/or frequent doses increase risk of thromboembolism. Lowest-approved dose recommended for mild to moderate bleeds. The mechanism involves additive and synergistic increase in thrombin generation. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Concizumab Class
- Tissue Factor Pathway Inhibitor Antagonist
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Additive and synergistic increase in thrombin generation
What To Tell Your Doctor or Pharmacist
If you are taking Concizumab and your doctor is considering prescribing Fviii (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider